Cytek Biosciences, Inc. (NASDAQ: CTKB) is a Healthcare company (Medical - Devices) with a market capitalization of $745M. The Maz Rating grades it against the other companies in its sector.
Cytek Biosciences, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $5.70, Cytek Biosciences, Inc. trades at 3.6x sales and 2.3x book value. Over the last twelve months it generated about $208M of revenue and a net loss of $83M. It runs a gross margin of 54.7%, an operating margin of -21.1% and a net margin of -39.1%. It shows return on equity of -24.7%, return on invested capital of -11.8% and a free cash flow yield of -1.8%. On the balance sheet: a debt-to-equity ratio of 0.08 and a current ratio of 4.46. Over the past 52 weeks the share price ranged from $3.31 to $6.34, with a beta of 1.14.
Cytek Biosciences, Inc. does not currently pay a dividend.
5 Wall Street analyst ratings cover the stock: 3 Buy, 1 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Cytek Biosciences, Inc. is a company dedicated to cell analysis solutions, offering advanced tools that facilitate scientific progress in both biomedical research and clinical settings. Their primary offerings include the Aurora and Northern Lights spectrum flow cytometers. These instruments conduct comprehensive cell analysis by leveraging fluorescence signatures from multiple lasers to differentiate between various fluorescent tags on individual cells. Complementing these, the Aurora Cell Sorter system utilizes full spectrum profiling technology to broaden the range of potential applications in cell analysis. Beyond instrumentation, Cytek provides essential reagents and kits. These include cFluor reagents, which are antibodies conjugated with fluorochromes, specifically designed to identify target cells for analysis on their systems. They also offer a 25-color immunoprofiling assay, a ready-to-use solution for pinpointing major human immune cell subpopulations like TBNK cells, monocytes, dendritic cells, and basophils. To streamline laboratory operations, the company offers automated micro-sampling and sample loader systems. These automated plate loaders are engineered to integrate seamlessly with the Aurora and Northern Lights systems. The intuitive SpectroFlo software accompanies these systems, simplifying the workflow from quality control through to data analysis. Cytek also provides comprehensive customer support resources. Cytek's diverse client base includes pharmaceutical and biopharmaceutical companies, academic research institutions, and clinical research organizations. The company distributes its products through a direct sales force and dedicated support teams in North America, Europe, China, and the Asia-Pacific region. Additionally, it partners with distributors and sales agents to serve markets across European, Latin American, Middle Eastern, and other Asia-Pacific countries. Originally established in 1992 as Cytoville, Inc., the company officially adopted the name Cytek Biosciences, Inc. in August 2015. Its corporate headquarters are situated in Fremont, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Cytek Biosciences, Inc. (CTKB) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 1.22% / 30% · (Cash+Inv) / Mkt Cap (36m) 37.0% / 30% · Interest income / Revenue 1.92% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 1.22% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 37.0% / 33% · Receivables / Mkt Cap (36m) 8.80% / 49% · Interest income / Revenue 1.92% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 1.22% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 37.0% / 33.33% · Receivables / Mkt Cap (24m) 8.80% / 33.33% · Interest income / Revenue 1.92% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 2.65% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 57.8% / 33.33% · Receivables / Avg Assets (4Q) 13.3% / 33.33% · Interest income / Revenue 1.92% / 5% | Fail |
| FTSE | Debt / Total Assets 1.89% / 33.33% · (Cash+ST Inv) / Total Assets 57.4% / 33.33% · (Cash+Recv) / Total Assets 71.0% / 33.33% · Interest income / Revenue 1.92% / 5% | Fail |
No. As of September 2026, Cytek Biosciences, Inc. (CTKB) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Cytek Biosciences, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m).
About 1.92% of each dividend: Cytek Biosciences, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.